Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib for Acute Cellular Rejection in Kidney Transplant
NCT02351427Phase 3Unknown
- Sponsor
- Asan Medical Center
- Start
- Feb 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bortezomib in acute cellular rejection (ACR) (2 arms), sponsored by Asan Medical Center. Primary endpoint: Serum creatinine at Day 14. Status: unknown.
02
Drugs
bortezomib
03
Conditions
acute cellular rejection (ACR)
Beyond the preview
Go deeper on NCT02351427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02351427.